Voyager Therapeutics, Inc.
VYGR
Last
$2.45
Day
+3.4%
1y
-54.0%
5y
-7.4%
52w
-57.3%
SPY YTD
+13.3%
XLV
+8.1%
Earnings
2026-11-0929d
EMA 21
2.73
EMA 50
3.00
EMA 200
3.53
20d high
-26.2%
5y high
-83.5%
5y range
0th
Positions held
Your positionsVYGR isn't in your positions.
Add it to see shares, cost, and P&L here.
Score
-24
Hold
avoid
Signal
Strong Sell
Target
$2.64
Stop
$2.15
Stop distance
12.2%
Target vs last
+7.8%
Fundamentals
| Market cap | $146.03M | Enterprise value | $62.26M | Trailing P/E | — | Forward P/E | -1.85 |
| PEG | — | Price / book | 0.94 | Beta | 1.28 | Dividend yield | 0.00% |
| Revenue growth | -39.1% | Earnings growth | — | Gross margin | -2.4% | Operating margin | -8.3% |
| Profit margin | 0.0% | ROE | -54.1% | ROA | -27.3% | Debt / equity | 0.21 |
| Current ratio | 7.51 | Free cash flow | -$77.31M | Analyst recommendation | strong_buy | Mean target | $14.89 |
| 52w high | $5.55 | 52w low | $2.33 |
Quarterly
| 2026-Q2 | 2026-Q1 | 2025-Q4 | 2025-Q3 | 2025-Q2 | 2025-Q1 | |
|---|---|---|---|---|---|---|
| Revenue | $3.2M | $2.6M | $15.3M | $13.4M | $5.2M | — |
| Op margin | -833.9% | -1167.4% | -195.2% | -228.9% | -704.3% | — |
| Net income | -$24.5M | -$27.9M | -$27.4M | -$27.9M | -$33.4M | — |
| Gross margin | — | — | — | — | — | — |
| Gross profit | — | — | — | — | — | — |
| Operating income | -$26.4M | -$30.3M | -$29.9M | -$30.6M | -$36.6M | — |
- Revenue +22% vs prior quarter ($3.2M vs $2.6M).
- Operating margin expanded to -833.9%.
Yearly (6y)
| 2025 | 2024 | 2023 | 2022 | |
|---|---|---|---|---|
| Revenue | $40.4M | $80.0M | $250M | $40.9M |
| Op margin | -326.6% | -104.1% | 48.8% | -124.3% |
| Net income | -$120M | -$65.0M | $132M | -$46.4M |
| Gross margin | — | — | — | — |
| Gross profit | — | — | — | — |
| Operating income | -$132M | -$83.3M | $122M | -$50.8M |
Headline scan
No flags
• No distress or material-risk keywords in recent headlines (keyword scan only — not a guarantee).
News
2026-09-01 · Voyager to Present at Upcoming Investor Conferences
2026-08-06 · Voyager Therapeutics (VYGR) Reports Q2 Loss, Misses Revenue Estimates
2026-08-06 · Voyager Therapeutics: Q2 Earnings Snapshot
2026-08-06 · Voyager Reports Second Quarter 2026 Financial and Operating Results
2026-07-13 · Voyager Therapeutics Expects to Start Early Alzheimer's Study in Adults in H2
2026-07-13 · Can Biogen Convince Skeptics That Cutting a Rogue Protein Slows Alzheimer’s?
Price (daily)
Full chart · RSI · MACD · patternsVYGR · daily-24.5% over 13 sessions
Close EMA21 EMA50 EMA200
Quarterly · revenue, net income, margins
Revenue Net income Gross margin Op margin